ArticleNature communications2020
Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 274 citations in OpenAlex.
- Microviscosity-gated excited-state partitioning in a NIR-II molecular rotor for disease imaging and imaging-guided photothermal therapy.Materials today. Bio · 2026Article
- Smart molecular design of NIR-II organic fluorophores through self-driven iterative evolution, deep learning, and fragment-based assembly.Smart molecules : open access · 2026Article
- Advanced imaging techniques for tumor intraoperative navigation imaging.Npj imaging · 2026Review
- Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling.Materials today. Bio · 2026Article
- Near-infrared (NIR) Fluorophores in Cancer Bioimaging and Therapy.Current medicinal chemistry · 2026Review
- Sunlight PDT leveraging NIR-II nanospray: painless, hemostatic, anti-inflammatory therapy towards diabetic wound infections.National science review · 2026Article
- Nitric oxide-activatable NIR-II organic small molecule for fluorescence imaging-guided synergistic photodynamic and photothermal therapy.Chemical science · 2025Article
- Harnessing Dye-Induced Local Heating in Lipid Membranes: A Path to Near-Infrared Light-Modulated Artificial Synaptic Vesicles.ACS nano · 2025Article
- Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy.Nature communications · 2025Article
- Application of NIR Fluorescent Materials in Imaging and Treatment of Tumors of Different Depths.Nanomaterials (Basel, Switzerland) · 2025Review
- Near-infrared II cyanine fluorophores with large stokes shift engineered by regulating respective absorption and emission.Nature communications · 2025Article
- Rabies Virus Targeting NIR-II Phototheranostics.Journal of the American Chemical Society · 2025Article
- Long-term in vivo immune tracking nanoplatform based on AgBMC biology · 2025Article
- Aqueous up-conversion organic phosphorescence and tunable dual emission in a single-molecular emitter.Chemical science · 2025Article
- NIR-II Emissive Persistent Neutral π-Radical with Rapid Doublet Internal Conversion for Efficient Cancer Photothermal Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition.Acta pharmaceutica Sinica. B · 2025Article
- Synthesis of a novel mitochondrial fluorescent probe - killing cancer cellsFrontiers in pharmacology · 2025Article
- A LDH-Derived Metal Sulfide Nanosheet-Functionalized Bioactive Glass Scaffold for Vascularized Osteogenesis and Periprosthetic Infection Prevention/Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2024Review
- An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes.European journal of nuclear medicine and molecular imaging · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NIR-II fluorophores have shown great promise for biomedical applications with superior in vivo optical properties. To date, few small-molecule NIR-II fluorophores have been discovered with donor-acceptor-donor (D-A-D) or symmetrical structures, and upconversion-mitochondria-targeted NIR-II dyes have not been reported. Herein, we report development of D-A type thiopyrylium-based NIR-II fluorophores with frequency upconversion luminescence (FUCL) at ~580 nm upon excitation at ~850 nm. H4-PEG-PT can not only quickly and effectively image mitochondria in live or fixed osteosarcoma cells with subcellular resolution at 1 nM, but also efficiently convert optical energy into heat, achieving mitochondria-targeted photothermal cancer therapy without ROS effects. H4-PEG-PT has been further evaluated in vivo and exhibited strong tumor uptake, specific NIR-II signals with high spatial and temporal resolution, and remarkable NIR-II image-guided photothermal therapy. This report presents the first D-A type thiopyrylium NIR-II theranostics for synchronous upconversion-mitochondria-targeted cell imaging, in vivo NIR-II osteosarcoma imaging and excellent photothermal efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.